SEARCH:   Advanced

Blood, 25 June 2009, Vol. 113, No. 26, pp. 6528-6532. Prepublished online as a Blood First Edition Paper on May 1, 2009; DOI 10.1182/blood-2009-03-211821. This Article Full Text (PDF) All Versions of this Article: blood-2009-03-211821v1 113/26/6528    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Kchour, G. Articles by Bazarbachi, A. Search for Related Content PubMed PubMed Citation Articles by Kchour, G. Articles by Bazarbachi, A. Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted March 18, 2009 Accepted April 22, 2009 Phase II study of the efficacy and safety of the combination of arsenic trioxide, interferon alpha, and zidovudine in newly diagnosed chronic ATL Ghada Kchour, Mahdi Tarhini, Mohamad-Mehdi Kooshyar, Hiba El Hajj, Eric Wattel, Mahmoud Mahmoudi, Hassan Hatoum, Hossein Rahimi, Masoud Maleki, Houshang Rafatpanah, S.A.Rahim Rezaee, Mojtaba Tabatabaei Yazdi, Abbas Shirdel, Hugues de The, Olivier Hermine, Reza Farid, and Ali Bazarbachi* Immunology research centre Bu-Ali Research institute, Mashhad University of Medical Sciences, Mashhad, Iran, Islamic Republic of Department of Pathology and Laboratory Medicine, Mashhad University of Medical Sciences, Mashhad, Iran, Islamic Republic of Department of Internal Medicine, Mashhad University of Medical Sciences, Mashhad, Iran, Islamic Republic of Department of Internal Medicine, American University of Beirut, Beirut, Lebanon Oncovirologie et Biotherapies, CNRS FRE 3011, Universite Claude Bernard, Centre Leon Berard, Hopital Edouard Herriot, Lyon, France Department of Dermatology, Mashhad University of Medical Sciences, Mashhad, Iran, Islamic Republic of Microbiology and Virology Research center, Bu-Ali Research institute, Mashhad University of Medical Sciences, Mashhad, Iran, Islamic Republic of Department of Pharmaceutical Biotechnology, College of Pharmacy, Tehran University of Medical Science, Tehran, Iran, Islamic Republic of UMR 7151 CNRS, Laboratoire Associe au Comite de Paris de la Ligue contre le Cancer, Paris, France CNRS UMR 8603 and Department of Hematology, Necker Hospital, Paris, France * Corresponding author; email: bazarbac{at}aub.edu.lb. Adult T-cell leukemia/lymphoma (ATL) is resistant to chemotherapy and carries a dismal prognosis particularly for the acute and lymphoma subtypes. Promising results were obtained with the combination of zidovudine and interferon-alpha. Chronic ATL has a relatively better outcome, but poor long-term survival is noted when patients are managed with a watchful-waiting policy or with chemotherapy. In ATL cell lines, arsenic trioxide shuts off constitutive NF-B activation and potentiates interferon-alpha apoptotic effects through proteasomal degradation of Tax. Clinically, arsenic/interferon therapy exhibits some efficacy in refractory aggressive ATL patients. These results prompted us to investigate the efficacy and safety of the combination of arsenic, interferon-alpha and zidovudine in 10 newly diagnosed chronic ATL patients. An impressive 100% response rate was observed including 7 complete remissions, 2 complete remissions but with more than 5% circulating atypical lymphocytes, and one partial response. Responses were rapid and no relapse was noted. Side effects were moderate and mostly hematological. In conclusion, treatment of chronic ATL with arsenic, interferon-alpha and zidovudine is feasible and exhibits an impressive response rate with moderate toxicity. Long-term follow up will clarify whether this will translate in disease cure. Overall, these clinical results strengthen the concept of oncogene targeted cancer therapy. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: R. Nasr, V. Lallemand-Breitenbach, J. Zhu, M.-C. Guillemin, and H. de The Therapy-induced PML/RARA Proteolysis and Acute Promyelocytic Leukemia Cure Clin. Cancer Res., October 15, 2009; 15(20): 6321 - 6326. [Abstract] [Full Text] [PDF]

	Copyright © 2009 by American Society of Hematology         Online ISSN: 1528-0020